Ekta Batra is a Senior Editor Pharma & Health at CNBC-TV18. With nearly 14 years of experience, she specializes in pharmaceuticals and healthcare, providing in-depth coverage of industry trends, investment strategies, and health news. Ekta's insights and analysis have been featured in outlets like Environmental Health News and MSN, and she is recognized for her podcast ‘TheMedicineBox’ and her award-winning coverage of COVID-19.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
India (National)
Not enough data
Ekta Batra's focus is on the Indian healthcare and pharmaceutical industry, particularly covering investment analysis and data-driven insights. She appears to be interested in articles that involve mergers, market trends, drug development, stocks, and other related topics within the pharmaceutical industry.
Given Ekta's emphasis on citing data and investment analysis, she would likely respond well to pitches from experts who can provide unique insights into market trends or specific data-backed analyses within the Indian pharmaceutical sector. Additionally, sources with expertise in mergers and acquisitions or stock recommendations may also find success when reaching out to her.
As Ekta's geographic focus is national (India), it’s important for pitches to keep this local perspective in mind when providing relevant information or expert commentary about the Indian pharmaceutical landscape.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Ekta Batra, Shloka Badkar
The US Food and Drug Association (USFDA) approved Foundayo for weight-loss on April 1, 2026. The drug has generated $98 million in global sales in the second quarter of 2026, divided between $67 million in the US and $31 million in the UAE.
By: Vinnii Motiwala, Ekta Batra, Sonal Bhutra
Rossari Biotech retains its 10–15% FY27 growth guidance and targets doubling profits in four years, with a focus on cash flows, B2B margins and Saudi Arabia expansion.
By: Ekta Batra
IPA seeks a holistic review of healthcare pricing after the NPPA capped margins on 137 cancer drugs, citing potential implications for hospitals and the pharma sector.
By: Vinnii Motiwala, Ekta Batra
Bernstein's Nandan Kulkarni also discusses India's drug discovery capabilities and the growth outlook for GLP-1 weight loss medicines.
By: Ekta Batra, Vinnii Motiwala, Sonal Bhutra
Dhruv Bhatia, Fund Manager-Equity at Edelweiss Mutual Fund, says the recent selloff in mid- and small-cap stocks is largely a phase of profit booking rather than a structural change in market leadership. He remains constructive on select mid-caps, private banks, autos and healthcare, while saying crude oil prices remain the biggest risk for markets. Here's what investors should watch next.
By: Sonal Bhutra, Vinnii Motiwala, Ekta Batra
Jupiter Life Line Hospitals expects margins to improve as its Dombivli hospital approaches break-even and newer facilities mature. CEO Ankit Thakker said ARPOB is likely to grow slightly ahead of inflation over the next few years, while the company remains on track with its expansion plans backed by cash reserves and internal accruals.
By: Ekta Batra, Gareema Bangad
Kotak expects Mankind Pharma's Earnings per share (EPS) to report a Compounded Annual Growth Rate (CAGR) of 23% over financial year 2026-2029. It identified the over-the-counter (OTC) business as a key concern, with growth yet to pick up.
By: Sonal Bhutra, Ekta Batra, Vinnii Motiwala
Eris Lifesciences expects profitability to improve as biologics production ramps up and acquired businesses continue to scale. The company also expects India's semaglutide market to grow significantly over the next year while planning faster debt reduction as its capex cycle slows.
By: Ekta Batra, Vinnii Motiwala, Sonal Bhutra
Uttam Kumar Srimal, Deputy Head-Fundamental Research at Axis Securities sees opportunities after the market correction, favouring private banks, metals, quick commerce, autos and hotels. DCB Bank and Coforge feature among its Diwali picks.
By: Ekta Batra, Vinnii Motiwala, Sonal Bhutra
The polystyrene maker expects volume growth of up to 5% in FY27, while exports could fall 70–75% for the full year unless shipping routes reopen and freight costs ease.
